It is also important to avoid angioedema triggers in HAE-nC1-INH, such as estrogen-containing oral contraceptives or estrogen replacement therapy, dipeptidyl peptidase-4 (DPP-4) inhibitors, neprilysin inhibitors and ACE inhibitors. This evidence concerns the gene COL18A1 and hereditary angioedema.